You are here

Vigabatrin Approved for Adult and Pediatric Epileptic Seizures

Adjunctive Therapy is First Generic Version of Sabril for Focal Seizures

The FDA has approved vigabatrin 500 mg tablets (Teva Pharmaceuticals USA) as an adjunctive therapy for complex partial seizures. The drug is indicated for treating focal seizures in patients aged 10 years and older who have responded inadequately to several alternative treatments.

Complex partial seizures begin in a specific part of the brain and can affect consciousness. They typically last between 30 and 90 seconds, and are often followed by disorientation, confusion, and/or fatigue.

Vigabatrin’s most common side effects include dizziness, fatigue, somnolence, involuntary eye movement, tremor, blurred vision, memory impairment, weight gain, arthralgia, upper respiratory tract infection, aggression, diplopia, abnormal coordination, and a confused state. Serious side effects include permanent vision loss and risk of suicidal thoughts or actions.

Source: PR Newswire, January 16, 2019

Recent Headlines

NY Hospitals Required to Implement Protocols in Suspected Cases
Presence of BOK Protein Key for Positive Treatment Response
Patient Access to Inhaler Use Data Could Improve Asthma Management
Overall Survival 4.3 Months’ vs. 1.5 Months for Traditional Regimens
Primary Immunodeficiencies Affect 250,000 People in U.S.
More Than 25% of Patients Responded to Xpovio/Dexamethasone Combo
Attacks Cancerous Cells, Leaves Healthy Tissues Alone
Moderates Pre-diabetes Progression, Reduces Cholesterol Levels